WO2006126488A1 - Extrait de sparassis crepu - Google Patents

Extrait de sparassis crepu Download PDF

Info

Publication number
WO2006126488A1
WO2006126488A1 PCT/JP2006/310151 JP2006310151W WO2006126488A1 WO 2006126488 A1 WO2006126488 A1 WO 2006126488A1 JP 2006310151 W JP2006310151 W JP 2006310151W WO 2006126488 A1 WO2006126488 A1 WO 2006126488A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
molecular weight
hanabiratake
composition
component
Prior art date
Application number
PCT/JP2006/310151
Other languages
English (en)
Japanese (ja)
Inventor
Yoshihiro Nishikawa
Takashi Kimura
Munehiko Dombo
Kiwamu Yuki
Original Assignee
Unitika Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unitika Ltd. filed Critical Unitika Ltd.
Priority to JP2007517815A priority Critical patent/JPWO2006126488A1/ja
Publication of WO2006126488A1 publication Critical patent/WO2006126488A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to an extract of Hanabira bamboo mainly composed of a relatively low molecular weight component obtained from the fruit body or mycelia of Hanabiratake, and an antitumor agent, cosmetic and health food containing the same as an active ingredient .
  • Mushrooms have been used for food since ancient times, but in recent years, the physiological activity of the components has been clarified. Among them, krestin, lentinan, schizophyllan (all trade names) are recognized as useful as pharmaceuticals, and agaritas, mesimacob, ganoderma, etc. are expected to have an immunostimulatory effect and an antitumor effect. Attempts have been made to use dried or extracted substances or mycelia as health food ingredients. For example, Mannentake has been tried to use fruit bodies or extracts thereof as raw materials for health foods (see, for example, Patent Documents 1, 2, and 3).
  • Hanabiratake (Sparassis crispa), which belongs to these mushrooms, is a mushroom that grows in larch and the like, and is characterized by its pure white color that is crunchy and its shape like leaf peony. It is an edible mushroom. Up until now, it has been said that this bamboo shoot has slow growth and is extremely difficult to cultivate artificially. However, in recent years, a new cultivation method that can be cultivated in a relatively short period of time has been established and can be supplied on a commercial scale. (For example, see Patent Documents 4 and 5).
  • Non-Patent Documents 1 and 2 The active ingredient is said to be
  • Patent Document 1 Japanese Patent Laid-Open No. 2001-10970
  • Patent Document 2 Japanese Patent Laid-Open No. 2001-131083
  • Patent Document 3 Japanese Patent Laid-Open No. 2003-183176
  • Patent Document 4 Japanese Patent Laid-Open No. 11-56098
  • Patent Document 5 Japanese Patent Laid-Open No. 2002-369621
  • Non-Patent Document 1 Biol. Pharm. Bull. 23 (7) 866-872 (2000)
  • Non-Patent Document 2 Biol. Pharm. Bull. 25 (7) 931—939 (2002)
  • Patent Document 6 Japanese Unexamined Patent Publication No. 2000-217543
  • ⁇ -glucan which is considered to be the main component of the antitumor activity of mushrooms, has a molecular weight of about several millions, and generally cannot necessarily be absorbed from the digestive tract. Therefore
  • an antitumor component having a lower molecular weight and good absorption of gastrointestinal tract has been strongly desired.
  • An object of the present invention is to provide a low molecular weight antitumor component derived from the fruit body or mycelium of Hanabiratake and an antitumor agent, a cosmetic and a health food containing the same as an active ingredient.
  • the present invention is a solvent extract of Hanabiratake, the main component is a molecular weight of 500 ⁇
  • the gist of the extract of the flower is a component within the range of 10,000, and another invention is a component of the solvent extract of the flower with a molecular weight of 500 to 1000 using a dialysis membrane.
  • a component having a molecular weight in the range of 500 to 10,000 is separated from the solvent extract of Hanabiratake by gel filtration.
  • the main component is a component having a molecular weight in the range of 500 to 10000 by performing ethanol precipitation from a solvent extract of Hanabiratake.
  • the gist of the extract is a garlic bamboo extract obtained by fractionation.
  • another invention is characterized by an antitumor agent containing the above-mentioned extract of nobira and nabiratake as an active ingredient, and another invention provides a cosmetic containing the above-mentioned extract of vanilla bamboo as an active ingredient. It is intended as a summary Still another invention is summarized as a health food containing the above-mentioned Hanabiratake extract as an active ingredient.
  • the present invention also provides a method for treating tumors or a method for inhibiting the growth of tumor cells by administering the above-mentioned solvent extract of Hanabiratake to a subject, and further comprising the solvent extract of Hanabiratake for the production of an antitumor agent. Also provides use.
  • the present invention since it is a low molecular weight component having a molecular weight in the range of 500 to 10,000, it is excellent in absorption of gastrointestinal strength when administered orally, and as a result, has an effect of improving antitumor activity. .
  • FIG. 1 is a graph showing the molecular weight distribution (analysis result by GPC method) of the fruit extract of the present invention (hot water extract and low molecular weight antitumor component).
  • FIG. 2 is a graph showing the results of a tumor growth inhibition test by oral ingestion of the extract of the present invention (the change in tumor size over time).
  • Hanabiratake is a mushroom that occurs specifically in coniferous forests such as larch at an altitude of 1000 meters or higher, and has been called a “phantom mushroom” because it is difficult to find.
  • the cultivation has been difficult and generally not well known, but in recent years, artificial cultivation methods have been established and mass production has become possible.
  • the fruit body used in the present invention is not particularly limited in its production method, and may be a natural product or a product obtained by artificial cultivation.
  • Artificial cultivation can be carried out by preparing a conventionally known bacterial bed for artificial cultivation (for details, see JP-A-11-56098, JP-A-2002-369621 and JP-A-2002-369621). 2002-125460, US Pat. No. 6,212,822, etc.).
  • the mycelium mycelium used in the present invention can be obtained by a conventional liquid culture method.
  • a commonly used carbon source such as dextrin and glycerol can be used in addition to a monosaccharide such as glucose.
  • Inorganic or nitrogen sources Can use an organic nitrogen source, but it is preferable to use an organic nitrogen source in terms of growth rate.
  • adding growth factors such as trace elements and vitamins as needed is no different from normal culture.
  • the culture temperature is preferably 15 ° to 30 °°, and 11 is preferably 2.5 to 8.0. It is preferable to add an insoluble component to the medium component because it can grow uniformly.
  • the culture period can be set to several days or several weeks depending on the strain.
  • the form of the bamboo shoot is not particularly limited, and may be as it is, or may be a freeze-dried product or a fine powder of a dried product. Of these, a dry powder of fine powder is preferable from the viewpoint of extraction efficiency.
  • Examples of the extraction solvent used in the extraction step include water, methanol, ethanol, isopropyl alcohol, butanol, glycerin, ethylene glycol, 1,3-butylene glycol, acetone, black mouth form, ethyl acetate, hexane, ether, and the like. Can be used. Among these, hot water is more preferable even though water is preferred.
  • the extraction method using hot water is not particularly limited. For example, add 5 to LOO times the amount of water to the dried powder of the fruit body or mycelium, and add 80 to 100 ° C (100 to 121 under high pressure conditions). Boil (heat) for 20 minutes to 3 hours at ° C), or add 5 to LOO times the amount of water to the dry powder and heat to reflux for 1 to 3 hours. Any method may be used such as repeating the hot water extraction treatment several times.
  • the solvent extract thus obtained contains components having a molecular weight in the range of 500 to 10,000
  • the low molecular weight components may be fractionated from the solvent extract.
  • the method of fractionation is not particularly limited, and examples thereof include a method using a dialysis membrane, a gel filtration method or a method using ethanol precipitation. Specifically, it can be performed as follows.
  • the solvent extract obtained as described above is made into a dried product by freeze-drying treatment, and then redissolved in an appropriate amount of water so that the molecular weight cut-off is in the range of 5,000 to 10,000.
  • Dialysis is performed using a certain dialysis membrane.
  • Specific examples of dialysis membranes include Funakoshi, Spectra Biotech membrane series, Spectra Z-pore CE series, and RC series. Distilled water may be used for the external dialysis solution, but sodium acetate, sodium hydroxide, urea, etc. are appropriately added to the dialysis internal solution prepared from the dried solvent extract depending on the solubility of the dried product. .
  • dialysis solution distilled water
  • a membrane tube
  • a component having a molecular weight in the range of 500 to 10,000 is obtained in the permeation liquid. It is also possible to increase the recovered amount of the dialysis liquid fraction by repeating the dialysis step several times.
  • the dried product of the solvent extract obtained in the same manner as described above is dissolved in an appropriate concentration, and passed through a glass column packed with a gel filtration carrier, so that the molecular weight is reduced.
  • a gel filtration carrier examples include Cefacryl series and Cefadex series manufactured by Amersham Almacia Biotech.
  • the solvent extract obtained in the same manner as described above is dissolved in 75% ethanol, and the insoluble precipitate is removed to obtain a molecular weight of 500 to 10,000 in the supernatant. Components in the range can be obtained.
  • the molecular weight obtained in this way is in the range of 500 to 10,000, preferably in the range of 20000 to 8000, more preferably in the range of 4,000 to 6000, and most preferably
  • the extract of the chanterelle mushroom which is mainly composed of a component having a molecular weight of about 5000, has a high antitumor activity. This is thought to be due to the fact that the absorption of gastrointestinal force was promoted due to the low molecular weight of this component, or that the immune activity in the intestinal tract was improved.
  • the molecular weight is determined by the GPC method (column; UltrahydrogelGuard + 120 + 500; manufactured by Waters, mobile phase; 0.5M phosphate buffer (pHll), flow rate; 0.5mLZ, detection; differential refractive index, estimation
  • the molecular weight is calculated from the retention time of dextran of each molecular weight).
  • the component having a molecular weight in the range of 500 to 10000 is preferably 80 to 100% by weight, more preferably 90 to 100% by weight, most preferably, in the dry weight of the extract of the present invention. Is 95% to 100% by weight.
  • the garlic bamboo extract composition of the present invention hardly contains ⁇ -glucan having a molecular weight of about several millions, and the dry weight of the garlic bamboo extract composition of the present invention contains j8 glucan having a molecular weight of about several millions.
  • the amount is 5% by weight or less, preferably 1% by weight or less.
  • the antitumor composition, antitumor agent, cosmetic product or health food of the present invention contains the extract of the bamboo shoot obtained as described above as an active ingredient, and further, a pharmaceutically acceptable carrier or cosmetic. Containing an acceptable carrier or a food acceptable as a health food and / or a beverage.
  • the content of the extract is not particularly limited because it is an extremely safe mushroom with food experience, but the lower limit is generally an amount that exhibits an effect according to the purpose of prevention or treatment.
  • the upper limit is easy-to-use, economic power, and other viewpoints.
  • the content and intake amount may be set so that 50 mg to 50 g can be ingested.
  • the dosage is such that the adult can take 0.25 mg to 2.5 g, preferably 2.5 mg to 2.5 g per day, in terms of dry weight. What is necessary is just to set intake.
  • the form of the antitumor agent, cosmetic or health food of the present invention is not particularly limited, and is in any form such as tablet, capsule, powder, granule, liquid, suspension, cream, etc. Available.
  • Various carriers that are pharmaceutically acceptable can be added to the antitumor agent of the present invention.
  • it may contain excipients, binders, disintegrants, lubricants, flavoring agents, coloring agents, sweeteners, corrigents, solubilizers, suspending agents, emulsifiers, coating agents.
  • excipients binders, disintegrants, lubricants, flavoring agents, coloring agents, sweeteners, corrigents, solubilizers, suspending agents, emulsifiers, coating agents.
  • the cosmetics of the present invention are cosmetics, quasi drugs, aqueous components used in pharmaceuticals, oily components, plant extracts, animal extracts, powders, surfactants, oils, alcohols, pH adjusters, preservatives, It is adjusted by appropriately blending antioxidants, thickeners, pigments, fragrances and the like as necessary.
  • the cosmetic of the present invention may contain other active ingredients such as a whitening agent, a moisturizing agent, an anti-inflammatory agent, and an ultraviolet absorber in addition to the above.
  • the health food of the present invention is prepared in the form of moss, bread, candy, jelly, cookie, soup by blending the extract of the solvent extract of the present invention into the raw material of food and drink so as to have the above blending amount. It can be.
  • inorganic components such as iron and calcium, various vitamins, dietary fibers such as oligosaccharides and chitosan, proteins such as soybean extract, Lipids such as tin and sugars such as sucrose and lactose can also be added.
  • the subject of the present invention is not particularly limited as long as the effect is exhibited, but is preferably a warm-blooded animal, more preferably a mammal, and most preferably a human.
  • Hanabira bamboo fruit bodies were produced by the following method.
  • a fungus bed substrate was prepared.
  • the fungus bed base material (520 g) was placed in an 850 cc polypropylene culture bottle, and the culture bottle was sterilized according to a conventional method, followed by inoculation with an inoculum of Hanabiratake (16 g). Thereafter, the fruit bodies of the bamboo leaf were harvested by culturing the culture bottle at a temperature of 23 ° C. for 56 days.
  • the weight of the fruiting body was 140 g per culture bottle
  • Hanabiratake mycelium was produced by the following method.
  • Example 1 Preparation of small body anti-tumor component of Hanabiratake fruit body
  • the dried fruit of Nabinotake mushroom fruit obtained in Production Example 1 was made into a powder with a blender, and 2 g of water was added to 50 g of the dried product, followed by extraction at 100 ° C. for 2 hours. The supernatant was collected by centrifugation, and the same extraction operation was repeated twice more on the precipitate. Recovered The supernatant was freeze-dried to obtain 23 g of extract (Hanabiratake fruiting body hot water extract; SCFHEx). The extract was again dissolved in 500 mL of water, and dialyzed with a dialysis membrane having a molecular weight of 8000 cut (Funakoshi, Spectranotech membrane pore 1.1). The dialyzed external solution was collected and freeze-dried to obtain 2.3 g (referred to as SCFHL) of a small-sized anti-tumor component of the fruit body of Hanabiratake.
  • SCFHL dialysis membrane having a molecular weight of 8000 cut
  • the dry matter of the mycelium of Nabinotake mushroom obtained in Production Example 2 was made into a powder by using a blender, and 200 mL of water was added to 5 g of the dried powder, followed by extraction at 100 ° C. for 1 hour. The supernatant collected by centrifugation was freeze-dried to obtain 1.6 g of extract (Hanabiratake mycelium hot water extract; SCMHEx). The extract was again dissolved in 200 mL of water and dialyzed with a dialysis membrane having a molecular weight of 8000 cut (Funakoshi, Spectra Biotech Membrane Pore 1.1). The dialyzed external solution was collected and freeze-dried to obtain 0.62 g (referred to as SCMHL) of Hanabiratake mycelium low molecular weight antitumor component.
  • SCMHL a dialysis membrane having a molecular weight of 8000 cut
  • the dried fruit of Nabinotake mushroom fruit obtained in Production Example 1 was made into a powder with a blender, and 2 g of water was added to 50 g of the dried product, followed by extraction at 100 ° C. for 2 hours. The supernatant was collected by centrifugation, and the same extraction operation was repeated twice more on the precipitate. The collected supernatant is freeze-dried, and lg of the resulting extract is dissolved in 50 mL of water, and the flow rate is 200 mmZ on a column ( ⁇ 30 mm X 900 mm, packing amount 500 mL) packed with Sephadex G-75 gel filtration carrier. It was applied at the same time and subsequently developed with distilled water.
  • the dried fruit body of Agarita statake was powdered with a blender, and 2 L of water was added to 36 g of the powder, and extraction was performed at 100 ° C for 2 hours. The supernatant is recovered by centrifugation and turned into a precipitate. The same extraction operation was repeated twice more. The collected supernatant was lyophilized to obtain 25 g of extract.
  • the extract was dissolved again in 500 mL of water and dialyzed with a dialysis membrane having a molecular weight of 8000 cut (Funakoshi, Spectra Biotech Membrane Pore 1.1). The dialyzed external solution was collected and freeze-dried to obtain 10.9 g (ABF HL).
  • Test Example I Quantitative determination of j8 dulcan
  • the amount of j8 glucan was quantified by the Congo-Red method with respect to the extract of Shiratake mushroom hot water (SCFHEx, SCMHEx) and the low molecular weight antitumor component (SCFHL, SCMHL) prepared according to Examples 1 and 2. Each 2% aqueous solution was prepared and ⁇ -glucan was quantified using Congo Red reagent. SCFEx was 5 mgZmL (25% solids), SCMEx was lmgZmL (5% solids) ⁇ -glucan. The low molecular weight component obtained by fractionation, SCFHL, is 0.08 mg / mL (0.4% solids) or less, and SCMHL is 0.03 mg / mL (0. Only the following j8 glucan was detected.
  • the j8 glucan quantified by the Congo-Red method is said to have a molecular weight of 100,000 or more.
  • Test Example 4 [cancer cell growth inhibition test]
  • Nobunatake bamboo fruit body hot water extract (SCFHEx), Hanabiratake mycelium hot water extract (SCMHEx), Hanabiratake fruit body small molecule antitumor component (SCFHL), Hanabiratake mycelium small molecule antitumor component prepared in Example 2 ( SCMHL) and Agaric statake fruit body small molecule antitumor component (ABFHL) prepared in Comparative Example 1 were dissolved in phosphate buffer (PBS, pH 7.2) and adjusted to a concentration of lOmgZmL.
  • Human colon cancer cells (Caco-2) or human leukemia cells (HL-60) are suspended in RPMI1640-10% urine serum medium (pH 7.2) to a concentration of 60,000 ZmL.
  • the low molecular weight anti-tumor component of the present invention exhibits an effect of suppressing the growth of cancer cells, and its strength is significantly higher than that of a mere hot water extract.
  • the fractionation by dialysis membrane is effective for exerting the growth inhibitory effect of cancer cells. It became clear that it was effective.
  • Test Example 5 Tumor Growth Inhibition Test by Ingestion
  • mice The mouse (ICR: Jcl, 6 weeks old, female, 10 animals in group Z) was suspended in ⁇ ⁇ MEM serum-free medium (pH 7.2) at a concentration of 40000000 / mL in the lower right limb.
  • Mouse sarcoma cells (SI 80) were transplanted at 50 ⁇ L each.
  • the low-molecular weight anti-tumor component of the present invention shows an effect of suppressing the growth of cancer cells, and its strength is higher than that of a mere hot water extract.
  • Each increase was about 10%, and it became clear that fractionation with a dialysis membrane was effective in exerting an inhibitory effect on the growth of cancer cells.
  • the present invention provides an extract of Hanabiratake, whose main component is a relatively low molecular weight component obtained from the fruit body or mycelia of Hanabiratake, and an antitumor agent, cosmetic and health food containing the same as an active ingredient.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cosmetics (AREA)

Abstract

L’invention concerne une substance antitumorale de poids moléculaire relativement faible ayant une excellente activité pharmacologique et qui peut être absorbée facilement à travers le tractus digestif, et un agent antitumoral, un produit cosmétique et un aliment diététique comprenant la substance comme ingrédient actif. Une composition d’extrait de Sparassis crépu comprenant, comme ingrédient principal, une substance ayant un poids moléculaire de 500 à 10000, la substance étant produite par lyophilisation d’un corps carpophore ou d’un mycélium d’un Sparassis crépu (Sparassis crispa), en formant le matériau séché en une poudre fine, en extrayant la poudre avec un solvant et en fractionnant l’extrait ; et une composition antitumorale, un produit cosmétique et un aliment diététique comprenant l’extrait de Sparassis crépu comme ingrédient actif.
PCT/JP2006/310151 2005-05-25 2006-05-22 Extrait de sparassis crepu WO2006126488A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007517815A JPWO2006126488A1 (ja) 2005-05-25 2006-05-22 ハナビラタケ抽出物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005152454 2005-05-25
JP2005-152454 2005-05-25

Publications (1)

Publication Number Publication Date
WO2006126488A1 true WO2006126488A1 (fr) 2006-11-30

Family

ID=37451914

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/310151 WO2006126488A1 (fr) 2005-05-25 2006-05-22 Extrait de sparassis crepu

Country Status (2)

Country Link
JP (1) JPWO2006126488A1 (fr)
WO (1) WO2006126488A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008007481A (ja) * 2006-06-30 2008-01-17 Unitika Ltd 血管新生阻害剤
JP2011102286A (ja) * 2009-04-27 2011-05-26 Iwade Kingaku Kenkyusho:Kk 脂肪減少等の活性を示す組成物
WO2018168879A1 (fr) * 2017-03-13 2018-09-20 学校法人東京女子医科大学 Composition ayant une action similaire à celle de l'œstrogène, médicament, aliment et boisson la contenant, procédé de production d'une composition ayant une action similaire à celle de l'œstrogène et méthode d'utilisation d'une séquence de base d'adn de sparassis crispa

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10298099A (ja) * 1997-04-23 1998-11-10 Kozo Niwa 細胞賦活組成物
JP2000159808A (ja) * 1998-11-27 2000-06-13 Kobayashi Pharmaceut Co Ltd 担子菌類菌糸体抽出物の分離、精製方法
JP2000217543A (ja) * 1999-01-29 2000-08-08 Nakajima Mitsuhiro ハナビラタケ抽出物
WO2001051070A1 (fr) * 2000-01-12 2001-07-19 Life Science Laboratories Co., Ltd. Substance eem-s physiologiquement active issue de champignons, methode de production de ladite substance et medicaments
WO2003051382A1 (fr) * 2001-12-14 2003-06-26 Sundory Co., Ltd. Procédé d'induction d'apoptose et compositions pour cette dernière
JP2004350620A (ja) * 2003-05-30 2004-12-16 Unitika Ltd 亜鉛分補給用食品材料

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10298099A (ja) * 1997-04-23 1998-11-10 Kozo Niwa 細胞賦活組成物
JP2000159808A (ja) * 1998-11-27 2000-06-13 Kobayashi Pharmaceut Co Ltd 担子菌類菌糸体抽出物の分離、精製方法
JP2000217543A (ja) * 1999-01-29 2000-08-08 Nakajima Mitsuhiro ハナビラタケ抽出物
WO2001051070A1 (fr) * 2000-01-12 2001-07-19 Life Science Laboratories Co., Ltd. Substance eem-s physiologiquement active issue de champignons, methode de production de ladite substance et medicaments
WO2003051382A1 (fr) * 2001-12-14 2003-06-26 Sundory Co., Ltd. Procédé d'induction d'apoptose et compositions pour cette dernière
JP2004350620A (ja) * 2003-05-30 2004-12-16 Unitika Ltd 亜鉛分補給用食品材料

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008007481A (ja) * 2006-06-30 2008-01-17 Unitika Ltd 血管新生阻害剤
JP2011102286A (ja) * 2009-04-27 2011-05-26 Iwade Kingaku Kenkyusho:Kk 脂肪減少等の活性を示す組成物
WO2018168879A1 (fr) * 2017-03-13 2018-09-20 学校法人東京女子医科大学 Composition ayant une action similaire à celle de l'œstrogène, médicament, aliment et boisson la contenant, procédé de production d'une composition ayant une action similaire à celle de l'œstrogène et méthode d'utilisation d'une séquence de base d'adn de sparassis crispa
JPWO2018168879A1 (ja) * 2017-03-13 2020-02-20 学校法人東京女子医科大学 エストロゲン様作用組成物と、これを含む医薬、飲食品、エストロゲン様作用組成物の製造方法およびハナビラタケのｄｎａ塩基配列の利用法

Also Published As

Publication number Publication date
JPWO2006126488A1 (ja) 2008-12-25

Similar Documents

Publication Publication Date Title
EP1247529B1 (fr) Substance eem-s physiologiquement active issue de champignons, methode de production de ladite substance et medicaments
AU2006273203B2 (en) Strain of turkey tail mushroom, extract from the same, and use of the same
WO2017008768A1 (fr) Glucane et procédé de préparation de ce dernier, et application dans la préparation de médicaments et d'aliments fonctionnels stimulants immunitaires et antitumoraux.
Admassu et al. Development of functional foods: seaweeds (algae) untouched potential and alternative resource—a review
TWI724352B (zh) 具有抗癌、抗病毒、抗發炎、促進成骨細胞增生、促進腸道幹細胞增生的多醣醱酵組合物及其製備方法
JP4369258B2 (ja) 免疫賦活剤
KR20060116463A (ko) 인삼박을 배지로 한 버섯 균사체 및 그 생산방법
GIaVaSIS Polysaccharides from medicinal mushrooms for potential use as nutraceuticals
WO2006126488A1 (fr) Extrait de sparassis crepu
JP2004315512A (ja) 機能性組成物
JP4451100B2 (ja) タモギタケ子実体組成物を有効成分として含有する免疫賦活剤、及び抗癌剤
JP4203965B2 (ja) バシディオマイセテス及びバシディオマイセテス抽出組成物並びに健康食品及び免疫賦活剤
WO2004082691A1 (fr) Composition renfermant un oligomere de glucane soluble issu de saccharomyces cerevisiae is2 aux fins d'activation immune ou de prevention et de traitement du cancer et procede de preparation de celle-ci
Wu et al. Bioactive ingredients and medicinal values of Grifola frondosa (Maitake). Foods 2021; 10: 95
JP2009143854A (ja) 創傷治癒促進剤
KR20050006533A (ko) 해조류로부터 항암 및 면역활성 추출물을 추출하는 방법
KR20120019311A (ko) 면역기능을 증진시키기 위하여 조제한 인삼의 상황버섯 균사체 발효물로부터 분리된 다당류를 유효성분으로 포함하는 면역활성용 조성물
KR100729213B1 (ko) 면역 증강 활성을 갖는 잎새 버섯의 액체배양물로부터분리한 세포외 생체고분자
JPH11302191A (ja) ハタケシメジ抽出物を活性成分とする免疫賦活剤及び抗腫瘍剤
JP5063040B2 (ja) 血管新生阻害剤
KR101116247B1 (ko) 미강으로부터 분리한 생리활성물질 및 그 제조방법
KR101345734B1 (ko) 참송이 버섯 유래 변성 베타글루칸을 함유하는 항암용 식품 조성물 또는 약학조성물
Zhang et al. Sulfation of Agrocybe chaxingu polysaccharides can enhance the immune response in broiler chicks
Pereira Algal polysaccharides
JPH11209301A (ja) 蛋白多糖体００４１

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007517815

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06746685

Country of ref document: EP

Kind code of ref document: A1